Proteomics characterization of extracellular vesicles sorted by flow cytometry reveals a disease-specific molecular cross-talk from cerebrospinal fluid and tears in multiple sclerosis

Several proteomics studies have been conducted to identify new cerebrospinal fluid (CSF) biomarkers in Multiple Sclerosis (MuS). However, the complexity of CSF and its invasive collection, limits its use. Therefore, the goal of biomarker research in MuS is to identify novel distinctive targets in CS...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Journal of proteomics Ročník 204; s. 103403
Hlavní autori: Pieragostino, Damiana, Lanuti, Paola, Cicalini, Ilaria, Cufaro, Maria Concetta, Ciccocioppo, Fausta, Ronci, Maurizio, Simeone, Pasquale, Onofrj, Marco, van der Pol, Edwin, Fontana, Antonella, Marchisio, Marco, Del Boccio, Piero
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: Netherlands Elsevier B.V 30.07.2019
Predmet:
angiogenesis
biomarkers
brain
cerebrospinal fluid
CSF
Extracellular vesicles
FACS sorting
flow cytometry
immune response
inflammation
monitoring
Multiple sclerosis
nervous system diseases
patients
proteins
Proteomics
sclerosis
Tears
Extracellular vesicles
FACS sorting
Multiple sclerosis
Tears
Proteomics
CSF
ISSN:1874-3919, 1876-7737, 1876-7737
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Several proteomics studies have been conducted to identify new cerebrospinal fluid (CSF) biomarkers in Multiple Sclerosis (MuS). However, the complexity of CSF and its invasive collection, limits its use. Therefore, the goal of biomarker research in MuS is to identify novel distinctive targets in CSF or in easily accessible biofluids. Tears represent an interesting matrix for this purpose, because (1) tears are related to the central nervous system (CNS) and (2) the CNS contains Extracellular Vesicles (EVs) derived from brain cells. These EVs are emerging new biomarkers associated to several neurological disorders. Here we applied an optimized flow cytometer for the identification and subtyping of EVs from CSF and tears. We found, for the first time, microglia-derived and neural-derived EVs in tears. The flow cytometer was used to sort and purify 106 EVs from untouched CSF and tears of MuS patients and healthy subjects. Purified EVs were analyzed with shotgun proteomics analysis, revealing that EVs from both CSF and tears of MuS patients conveyed similar proteins. Our data demonstrated a specific EVs-mediated molecular cross talk between CSF and tears, which opens the door to new diagnostic perspectives for MuS. Data are available via ProteomeXchange with identifier PXD013794. Proteomics characterization of released Extracellular Vesicles (EVs) in CSF and tears of Multiple Sclerosis patients represents a pioneering application that helped in recognizing information about the biologically relevant molecules. We found, for the first time, microglia-derived and neural-derived EVs in tears. Moreover, purified EVs revealed that both CSF and tears of Multiple Sclerosis patients conveyed similar proteins involved in inflammation, angiogenesis and immune response signalling. We think that our data will contribute to enhance knowledge in Multiple Sclerosis mechanisms and help in biomarker discovery. Moreover tears represent one of the most convenient body fluid for biomarker discovery in Multiple Sclerosis, since it is an high informative and easy accessible. The opportunity to export such a platform to a territory monitoring plan opens the door to new diagnostic perspectives for Multiple Sclerosis. [Display omitted] •Extracellular vesicles (EVs) FACS- purified have been used for proteomics.•Microglia-derived and neural-derived EVs were identified in tears.•Tears and CSF EVs convey similar proteins, in Multiple Sclerosis.•EV proteins deliver nuclear information and the program to insert it into the target cells.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1874-3919
1876-7737
1876-7737
DOI:10.1016/j.jprot.2019.103403